

CONTACTS: Trace Longo
Longo Communications
(714) 600-9811

Karen Mattocks
Vantage Oncology
(310) 335-4074

FOR IMMEDIATE RELEASE

VANTAGE ONCOLOGY ANNOUNCES MAJOR NATIONAL EXPANSION

**National Developer and Operator of Radiation Oncology Centers
Acquires Seven Centers, Opens Three New Centers and
Secures Credit Facility of \$100 Million**

Manhattan Beach, Calif. (July 16, 2008) Vantage Oncology, Inc. (“Vantage”), a national developer and operator of radiation oncology centers of excellence, announced today that it has recently completed seven new partnerships comprising 10 cancer treatment facilities in several new and existing markets. In addition, Vantage has secured a new \$100 million credit facility that will support the Company’s continued growth. Vantage now operates 31 centers in 11 states with its physician and hospital partners and is well positioned to continue its rapid national expansion.

The 10 new partnership centers include Radiation Medicine Specialists of Northeast PA in Wilkes-Barre, Pennsylvania, a partnership with Dr. Norman Schulman; Comprehensive Oncology Care in Exton, Pennsylvania, a partnership with Drs. Richard Yelovich and James Patton; Northern Boulevard Radiation Oncology Associates in Queens, New York, a partnership with Dr. Engracio Samala; and Cancer Care Centers of Brevard in Brevard and Indian River Counties, Florida, a partnership with Dr. Silas Charles that includes four centers. Additionally, Vantage has opened three new centers: Glendale Radiation Oncology in Glendale, California, a partnership with Valley Radiotherapy Associates; Rowlett Regional Cancer Center in Rowlett, Texas, a partnership with Dr. R. Steven Bradfield; and Streator Radiation Oncology in Streator, Illinois, a partnership with Dr. Neelima Kabre.

The new \$100 million credit facility has been provided by Ares Capital Corporation. This debt capital combined with equity capital from all five existing equity investors, New Enterprise Associates (NEA), CCP Equity Partners, Versant Ventures, Salix Ventures and Camden Partners, and three new investors, HLM Venture Partners, Meritech Capital Partners and Ares Capital Corp., will be used to further expand Vantage’s network of centers.

“We are very pleased with our national expansion efforts,” said Michael Fiore, Chief Executive Officer and co-founder of Vantage. “Since we began our operations just under six years ago, we have been building our infrastructure, enhancing our operating model, cultivating our relationships with high quality physician and hospital partners, and continuously strengthening our capital structure. The accomplishments of these past few months reflect the results of those efforts. We are now well positioned to continue this growth through new partnerships in both our existing and new regions. The acceptance of our partnership model and our focus on quality and advanced technology as we collaborate with our physician and hospital partners has been very positive. Our existing centers continue to expand and solidify their positions as leaders in their respective markets.”

Through its significant investment in technology, Vantage now provides Intensity Modulated Radiation Therapy (IMRT) at all of its affiliated centers, and Image Guided Radiation

Therapy (IGRT) at 26 centers. Within the next year, Vantage expects that all of its affiliated centers will have IGRT capability. Additionally, Stereotactic Radiosurgery (SRS) capabilities are available in six of its 10 regions, and are being expanded throughout the network. Starting this year, Vantage also expects to deploy intensity modulated arc therapy, a more efficient and precise radiation modality delivered with a single 360-degree rotation of the linear accelerator.

Vantage intends to become the first radiation oncology network to deploy a consistent, nationwide, quality-of-life-centered Electronic Medical Record (EMR). In conjunction with its physician partners, the Company is working to evolve its process of care based on the measured clinical outcomes from the EMR. To accomplish this goal, Vantage is working with one of the nation's largest radiation therapy systems providers to design the next generation of Vantage's clinical assessment and reporting systems. Deployment of this system began in the second half of 2007.

“We strongly believe that the future will be one in which evidence-based medicine and a demonstration of outcomes will be critical to successful cancer treatment,” said Leslie Botnick, M.D., Chief Medical Officer and co-founder of Vantage. “We intend to be a leader in the field of radiation oncology. Our physician partners are among the most respected clinicians in the industry and we are continuing to provide them with the tools and processes to demonstrate their clinical quality. Combining this capability with our regular investments in technologies that enhance patient care, it is clear that our centers provide our patients and their families with a quality of care equal to that of academic medical centers, but in locations much closer to home.”

The 10 regions in the Vantage network include the Santa Clarita and San Fernando Valleys in Southern California; the Inland Empire in Southern California; Central Texas; Chicago, Illinois; Evansville, Indiana; Cincinnati, Ohio; New York City; Eastern Pennsylvania; Central Florida; and Southern New England (Boston and Providence). The 31 centers currently provide over 200,000 patient treatments annually, including conventional, IMRT, IGRT, SRS and brachytherapy treatments. Vantage also provides medical physics services to its own centers as well as independent hospital and physician clients through its subsidiary, Vantage Oncology Physics, and provides billing services through its subsidiary, Vantage Medical Management Services.

ABOUT VANTAGE ONCOLOGY, INC.

Founded in October 2002, Vantage Oncology, Inc. (“Vantage”) acquires, joint ventures, develops and operates radiation oncology centers of excellence. The Company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage is led by a seasoned management team, including co-founder and Chief Executive Officer Michael Fiore, co-founder and Chief Medical Officer Leslie Botnick, M.D., Chief Financial Officer Marshal Salomon, Chief Development Officer Mark Ahern and Chief Technology Officer Christopher Rose, M.D. For more information about Vantage, visit www.vantageoncology.com.